Package Leaflet: Information for the User
Temozolomide Teva 5 mg hard capsules EFG
Temozolomide Teva 20 mg hard capsules EFG
Temozolomide Teva 100 mg hard capsules EFG
Temozolomide Teva 140 mg hard capsules EFG
Temozolomide Teva 180 mg hard capsules EFG
Temozolomide Teva 250 mg hard capsules EFG
temozolomide
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
Temozolomide Teva contains a medicine called temozolomide. This medicine is an antitumoral agent.
Temozolomide Teva is indicated for the treatment of patients with specific forms of brain tumors:
in adults with newly diagnosed glioblastoma multiforme. Temozolomide Teva is used initially in combination with radiotherapy (concomitant phase of treatment) and then alone (monotherapy phase of treatment).
in children aged 3 years and older and adults with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma. Temozolomide Teva is indicated for these tumors if they recur or worsen after standard treatment.
Do not take Temozolomide Teva
Warnings and precautions
Talk to your doctor, pharmacist, or nurse before taking Temozolomide Teva
Children and adolescents
Do not give this medicine to children under 3 years of age, as its effect in this age group has not been studied. There is limited information available in patients over 3 years who have taken Temozolomide Teva.
Using other medicines and Temozolomide Teva
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.
Pregnancy, breastfeeding, and fertility
If you are pregnant, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. You should not be treated with Temozolomide Teva during pregnancy unless clearly indicated by your doctor.
Effective contraceptive methods are recommended for female patients who can become pregnant during treatment with Temozolomide Teva and for at least 6 months after completing treatment.
You should stop breastfeeding while being treated with Temozolomide Teva.
Male fertility
Temozolomide Teva can cause permanent infertility. Male patients should use effective contraceptive methods and not get their partner pregnant during and for at least 3 months after completing treatment. It is recommended to consult about sperm preservation before treatment.
Driving and using machines
Temozolomide Teva may make you feel tired or sleepy. In this case, do not drive or use tools or machines, or ride a bicycle until you see how this medicine affects you (see section 4).
Temozolomide Teva contains lactose
If your doctor has told you that you have an intolerance to some sugars, consult with them before taking this medicine.
Temozolomide Teva contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per capsule; this is essentially "sodium-free".
Temozolomide Teva 20 mg hard capsules EFG contain orange yellow FCF (E110)Also, the body of the Temozolomide Teva 20 mg capsules contains the excipient orange yellow FCF (E110), which may cause allergic reactions.
Follow exactly the instructions for administration of this medicine given by your doctor or pharmacist. If you are unsure, consult your doctor or pharmacist again.
Dose and duration of treatment
Your doctor will determine the correct dose of Temozolomide Teva for you, based on your body size (height and weight), whether you have a recurrent tumor, and whether you have been previously treated with chemotherapy.
You may be prescribed another medicine (antiemetic) to take before and/or after taking Temozolomide Teva to prevent or control nausea and vomiting.
Patient with newly diagnosed glioblastoma multiforme
If you are a newly diagnosed patient, treatment will be carried out in two phases:
During the concomitant phase, your doctor will start with Temozolomide Teva at a dose of 75 mg/m2 (standard dose). You will take this dose every day for 42 days (up to a maximum of 49 days) in combination with radiotherapy. The dose of Temozolomide Teva may be delayed or interrupted, depending on your blood counts and how you tolerate the medication during the concomitant phase.
Once radiotherapy is completed, you will interrupt treatment for 4 weeks to allow your body to recover.
Then, you will start the monotherapy phase.
During the monotherapy phase, the dose and the way you take Temozolomide Teva will be different. Your doctor will tell you the exact dose. You may have up to 6 treatment cycles. Each cycle lasts 28 days. You will take your new dose of Temozolomide Teva once a day for the first 5 days of each cycle ("dosing days"). The first dose will be 150 mg/m2. Then, there will be 23 days without Temozolomide Teva. This adds up to a total treatment cycle of 28 days.
After Day 28, you will start the next cycle. You will take Temozolomide Teva once a day for 5 days, followed by 23 days without Temozolomide Teva. The dose of Temozolomide Teva may be adjusted, delayed, or skipped, depending on your blood tests and how you tolerate your medication during each treatment cycle.
Patient with recurrent or progressive tumors (malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma) taking only Temozolomide Teva
A treatment cycle with Temozolomide Teva is 28 days.
You will take Temozolomide Teva once a day for the first 5 days. This daily dose will depend on whether you have been previously treated with chemotherapy or not.
If you have not been previously treated with chemotherapy, your first dose of Temozolomide Teva will be 200 mg/m2 once a day for the first 5 days. If you have been previously treated with chemotherapy, your first dose of Temozolomide Teva will be 150 mg/m2 once a day for the first 5 days. Then, there will be 23 days without Temozolomide Teva. This adds up to a total treatment cycle of 28 days.
After Day 28, you will start a new cycle. You will take Temozolomide Teva once a day for 5 days, followed by 23 days without Temozolomide Teva.
Each time you start a new treatment cycle, your blood will be tested to check if your dose of Temozolomide Teva needs to be adjusted. Depending on the results, your doctor may adjust your medication for the next cycle.
How to take Temozolomide Teva
Take your prescribed dose of Temozolomide Teva once a day, preferably at the same time each day.
Take the capsules on an empty stomach; for example, at least one hour before you plan to have breakfast. Swallow the capsule(s) whole with a glass of water. Do not open, crush, or chew the capsules. If the capsule is damaged, avoid contact of the powder with your skin, eyes, or nose. If you accidentally get it in your eyes or nose, rinse the area with water.
Depending on the prescribed dose, you may need to take more than one capsule at a time, with different concentrations (active ingredient content, in mg). The color of the capsule cap is different for each concentration (see the table below).
Dose | Color/marking |
Temozolomide Teva 5 mg | two lines printed with green ink on the cap and "T 5 mg" printed with green ink on the body |
Temozolomide Teva 20 mg | two lines printed with orange ink on the cap and "T 20 mg" printed with orange ink on the body |
Temozolomide Teva 100 mg | two lines printed with pink ink on the cap and "T 100 mg" printed with pink ink on the body |
Temozolomide Teva 140 mg | two lines printed with blue ink on the cap and "T 140 mg" printed with blue ink on the body |
Temozolomide Teva 180 mg | two lines printed with red ink on the cap and "T 180 mg" printed with red ink on the body |
Temozolomide Teva 250 mg | two lines printed with black ink on the cap and "T 250 mg" printed with black ink on the body |
You must be sure you understand and remember the following:
Review the dose with your doctor each time you start a new cycle, as it may be different from the previous cycle.
Follow exactly the instructions for administration of Temozolomide Teva given by your doctor. If you have any doubts, consult your doctor or pharmacist. Errors in the way you take this medicine can have serious consequences for your health.
If you take more Temozolomide Teva than you should
If you accidentally take more Temozolomide Teva capsules than you should, contact your doctor, pharmacist, or nurse immediately.
If you forget to take Temozolomide Teva
Take the missed dose as soon as possible on the same day. If a whole day has passed, consult your doctor. Do not take a double dose to make up for the missed dose, unless your doctor tells you to do so.
If you have any other questions about the use of this medicine, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
Contact your doctor immediatelyif you have any of the following:
Treatment with Temozolomide Teva may cause a reduction in certain types of blood cells. This can make it more likely that you will have bruises or bleeding, anemia (reduction in the number of red blood cells), fever, and a reduced ability to fight infections. The reduction in blood cell count is usually temporary. In some cases, it may be prolonged and can cause a very severe form of anemia (aplastic anemia). Your doctor will frequently perform blood tests to detect any changes that may occur, and will decide if you need specific treatment. In some cases, the dose of Temozolomide Teva will be reduced or stopped.
Very common adverse effects (may affect more than 1 in 10 people) are:
Common adverse effects (may affect up to 1 in 10 people) are:
Uncommon adverse effects (may affect up to 1 in 100 people) are:
Reporting Adverse Effects:
If you experience adverse effects, consult your doctor, pharmacist, or nurse, even if they are not listed in this leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children, preferably in a locked cabinet. Accidental ingestion can be fatal in children.
Do not use this medicine after the expiration date stated on the label and carton after EXP. The expiration date is the last day of the month indicated.
Store in the original packaging.
Do not store above 30°C.
Keep the bottle tightly closed to protect it from moisture.
Inform your pharmacist if you notice any change in the appearance of the capsules.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of the packaging and any unused medicine. This will help protect the environment.
Composition of Temozolomide Teva
The active ingredient is temozolomide.
Temozolomide Teva 5 mg hard capsules: Each capsule contains 5 mg of temozolomide.
Temozolomide Teva 20 mg hard capsules: Each capsule contains 20 mg of temozolomide.
Temozolomide Teva 100 mg hard capsules: Each capsule contains 100 mg of temozolomide.
Temozolomide Teva 140 mg hard capsules: Each capsule contains 140 mg of temozolomide.
Temozolomide Teva 180 mg hard capsules: Each capsule contains 180 mg of temozolomide.
Temozolomide Teva 250 mg hard capsules: Each capsule contains 250 mg of temozolomide.
The other ingredients are:
Capsule content:
Capsule body:
Temozolomide Teva 5 mg hard capsules (including printing ink):gelatin, titanium dioxide (E 171), shellac, propylene glycol, aluminum lake indigo carmine (E132), yellow iron oxide (E172).
Temozolomide Teva 20 mg hard capsules (including printing ink): gelatin, titanium dioxide (E 171), shellac, propylene glycol, aluminum lake orange yellow FCF (E110).
Temozolomide Teva 100 mg hard capsules (including printing ink): gelatin, titanium dioxide (E171), red iron oxide (E172), shellac, propylene glycol, and yellow iron oxide (E172). Temozolomide Teva 140 mg hard capsules (including printing ink): gelatin, titanium dioxide (E171), shellac, propylene glycol, aluminum lake indigo carmine (E132).
Temozolomide Teva 180 mg hard capsules (including printing ink): gelatin, titanium dioxide (E171), shellac, propylene glycol, red iron oxide (E172).
Temozolomide Teva 250 mg hard capsules (including printing ink): gelatin, titanium dioxide (E171), shellac, propylene glycol, black iron oxide (E172), ammonium hydroxide (E527).
Product Appearance and Package Contents
Temozolomide Teva 5 mg hard capsuleshave a white opaque body and a cap with two lines printed with green ink on the cap and with “T 5 mg” printed with green ink on the body. Each capsule is approximately 16 mm in length.
Temozolomide Teva 20 mg hard capsuleshave a white opaque body and a cap with two lines printed with orange ink on the cap and with “T 20 mg” printed with orange ink on the body. Each capsule is approximately 18 mm in length.Temozolomide Teva 100 mg hard capsuleshave a white opaque body and a cap with two lines printed with pink ink on the cap and with “T 100 mg” printed with pink ink on the body. Each capsule is approximately 19.5 mm in length.
Temozolomide Teva 140 mg hard capsuleshave a white opaque body and a cap with two lines printed with blue ink on the cap and with “T 140 mg” printed with blue ink on the body. Each capsule is approximately 22 mm in length.
Temozolomide Teva 180 mg hard capsuleshave a white opaque body and a cap with two lines printed with red ink on the cap and with “T 180 mg” printed with red ink on the body. Each capsule is approximately 22 mm in length.
Temozolomide Teva 250 mg hard capsuleshave a white opaque body and a cap with two lines printed with black ink on the cap and with “T 250 mg” printed with black ink on the body. Each capsule is approximately 22 mm in length.
The hard capsules are presented in amber glass bottles containing 5 or 20 capsules.
Not all pack sizes may be marketed.
Marketing Authorization Holder and Manufacturer
Teva B.V.
Swensweg 5
2031GA Haarlem
Netherlands
Manufacturer
NerPharMa S.r.l.,
Viale Pasteur, 10
20014 Nerviano (MI)
Italy
Pharmachemie B.V.
Swensweg 5
2031 GA Haarlem
Netherlands
Haupt Pharma Amareg GmbH
Donaustaufer Stra?e 378
93055 Regensburg
Germany
Teva Operations Poland Sp. z o.o.
ul. Mogilska 80,
31-546 Kraków
Poland
You can request more information about this medicine by contacting the local representative of the Marketing Authorization Holder:
Belgium/Belgique/Belgien Teva Pharma Belgium N.V./S.A./AG Tel: +32 38207373 | Lithuania UAB Teva Baltics Tel: +370 52660203 |
Luxembourg/Luxemburg Teva Pharma Belgium N.V./S.A./AG Belgium/Belgien Tel: +32 38207373 | |
Czech Republic Teva Pharmaceuticals CR, s.r.o. Tel: +420 251007111 | Hungary Teva Gyógyszergyár Zrt. Tel: +36 12886400 |
Denmark Teva Denmark A/S Tlf: +45 44985511 | Malta Teva Pharmaceuticals Ireland Ireland Tel: +44 2075407117 |
Germany TEVA GmbH Tel: +49 73140208 | Netherlands Teva Nederland B.V. Tel: +31 8000228400 |
Estonia UAB Teva Baltics Eesti filiaal Tel: +372 6610801 | Norway Teva Norway AS Tlf: +47 66775590 |
Greece Specifar A.B.E.E. Τηλ: +30 2118805000 | Austria ratiopharm Arzneimittel Vertriebs-GmbH Tel: +43 1970070 |
Spain Teva Pharma, S.L.U. Tel: +34 913873280 | Poland Teva Pharmaceuticals Polska Sp. z o.o. Tel: +48 223459300 |
France Teva Santé Tél: +33 155917800 | Portugal Teva Pharma - Produtos Farmacêuticos, Lda. Tel: +351 214767550 |
Croatia Pliva Hrvatska d.o.o. Tel: + 385 13720000 | Romania Teva Pharmaceuticals S.R.L. Tel: +40 212306524 |
Ireland Teva Pharmaceuticals Ireland Tel: +44 2075407117 | Slovenia Pliva Ljubljana d.o.o. Tel: +386 15890390 |
Iceland Teva Pharma Iceland ehf. Sími: +354 5503300 | Slovakia TEVA Pharmaceuticals Slovakia s.r.o. Tel: +421 257267911 |
Italy Teva Italia S.r.l. Tel: +39 028917981 | Finland Teva Finland Oy Puh/Tel: +358 201805900 |
Cyprus Specifar A.B.E.E. Ελλáδα Τηλ: +30 2118805000 | Sweden Teva Sweden AB Tel: +46 42121100 |
Latvia UAB Teva Baltics filiale Latvija Tel: +371 67323666 | United Kingdom (Northern Ireland) Teva Pharmaceuticals Ireland Ireland Tel: +44 2075407117 |
Date of Last Revision of this Leaflet:
Other Sources of Information
Detailed information on this medicine is available on the European Medicines Agency website http://www.ema.europa.eu